ISDE India Edition 2026 spotlights minimally invasive therapies for esophageal cancer
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
Subscribe To Our Newsletter & Stay Updated